Nest Genomics closes $8.5 million seed financing round

US health tech company Nest Genomics has announced the closing of an $8.5 million seed financing round.

Nest is an end-to-end solution designed to help health systems, clinics, pharmaceutical companies and payers launch and scale longitudinal genomic programmes.

The funds raised will support Nest in launching its product with additional customers, integrating with more EMRs and expanding to other clinical specialty areas, including Paediatrics, Polygenic Risk Scores, and Pharmacogenetics.

The company also plans to automate and integrate other parts of the genetic testing process.

Moran Snir, Nest Genomics Co-Founder and CEO, said:

“Over the next decade, population genetic screening will be one of the most impactful public health interventions.

“To realise this potential, we must address the major challenges of incorporating genetic information into provider workflows and patient care.

“Nest Genomics is making it easy for health systems to launch and scale precision medicine while engaging patients across the continuum of care, helping them adhere to the latest clinical management guidelines, which include screenings, procedures, and medication.”

Nest has launched in several large health systems across the US.

So far, the platform supports hereditary cancers, cardiovascular genetics and conditions featured in the American College of Medical Genetics and Genomics’ secondary findings list.

Karen Page, General Partner at B Capital who led the round, said:

“Nest Genomics is bridging the gap between genomics and clinical practice so patients benefit from the shift to personalised medicine.

“Healthcare is in the early stages of the genomics transformation, and we are wholeheartedly enthusiastic about using patient specific data to more successfully treat disease.

“We are pleased to support the team as it revolutionises the industry.”

Nest founders Moran Snir and Guy Snir, have built several companies focused on increasing access to genetic information over the last decade.

Their previous company, Clear Genetics developed Gia (Genetic Information Assistant) – a chatbot that triages patients for genetic testing at the point of care.